Lilly's Oral Glp-1, Orforglipron, Demonstrated Statistically Significant Efficacy Results And A Safety Profile Consistent With Injectable Glp-1 Medicines In Successful Phase 3 Trial

April 17 (Reuters) - Eli Lilly and Co LLY.N:

• LILLY'S ORAL GLP-1, ORFORGLIPRON, DEMONSTRATED STATISTICALLY SIGNIFICANT EFFICACY RESULTS AND A SAFETY PROFILE CONSISTENT WITH INJECTABLE GLP-1 MEDICINES IN SUCCESSFUL PHASE 3 TRIAL

• ELI LILLY AND CO - ORFORGLIPRON REDUCES WEIGHT BY 16.0 LBS AT HIGHEST DOSE

• ELI LILLY AND CO - ORFORGLIPRON LOWERS A1C BY 1.3% TO 1.6% IN PHASE 3 TRIAL

• ELI LILLY AND CO - ORFORGLIPRON MEETS PRIMARY ENDPOINT OF A1C REDUCTION IN PHASE 3 TRIAL

• ELI LILLY AND CO - ORFORGLIPRON SAFETY PROFILE CONSISTENT WITH INJECTABLE GLP-1 THERAPIES

• ELI LILLY AND CO - COMMON ADVERSE EVENTS FOR ORFORGLIPRON WERE GASTROINTESTINAL-RELATED

• ELI LILLY AND CO - 65% OF PARTICIPANTS ON HIGHEST DOSE OF ORFORGLIPRON ACHIEVED A1C ≤ 6.5%

• ELI LILLY AND CO - TO SUBMIT ORFORGLIPRON FOR WEIGHT MANAGEMENT TO GLOBAL REGULATORY AGENCIES BY YEAR-END

• ELI LILLY - EXPECTS TO SUBMIT ORFORGLIPRON FOR WEIGHT MANAGEMENT, SUBMISSION FOR TREATMENT OF TYPE 2 DIABETES ANTICIPATED IN 2026